BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31666640)

  • 21. Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's cholesterol-decreasing efficacy in patients.
    Wu C; Zhao Y; Zhang Y; Yang Y; Su W; Yang Y; Sun L; Zhang F; Yu J; Wang Y; Guo P; Zhu B; Wu S
    J Adv Res; 2022 Mar; 37():197-208. PubMed ID: 35499044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabonomic Changes Associated with Atherosclerosis Progression for LDLR(-/-) Mice.
    Li D; Zhang L; Dong F; Liu Y; Li N; Li H; Lei H; Hao F; Wang Y; Zhu Y; Tang H
    J Proteome Res; 2015 May; 14(5):2237-54. PubMed ID: 25784267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
    Pirillo A; Catapano AL
    Atherosclerosis; 2015 Dec; 243(2):449-61. PubMed ID: 26520899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of enterocyte stearoyl-Co-A desaturase-1 in LDLR-null mice.
    Mukherjee P; Hough G; Chattopadhyay A; Grijalva V; O'Connor EI; Meriwether D; Wagner A; Ntambi JM; Navab M; Reddy ST; Fogelman AM
    J Lipid Res; 2018 Oct; 59(10):1818-1840. PubMed ID: 30139760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional analysis of the TRIB1 associated locus linked to plasma triglycerides and coronary artery disease.
    Douvris A; Soubeyrand S; Naing T; Martinuk A; Nikpay M; Williams A; Buick J; Yauk C; McPherson R
    J Am Heart Assoc; 2014 Jun; 3(3):e000884. PubMed ID: 24895164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine.
    Brusq JM; Ancellin N; Grondin P; Guillard R; Martin S; Saintillan Y; Issandou M
    J Lipid Res; 2006 Jun; 47(6):1281-8. PubMed ID: 16508037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daming capsule, a hypolipidaemic drug, lowers blood lipids by activating the AMPK signalling pathway.
    Bian Y; Li X; Li X; Ju J; Liang H; Hu X; Dong L; Wang N; Li J; Zhang Y; Yang B
    Biomed Pharmacother; 2019 Sep; 117():109176. PubMed ID: 31387185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
    Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
    Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
    Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet.
    Chang XX; Yan HM; Xu Q; Xia MF; Bian H; Zhu TF; Gao X
    Lipids Health Dis; 2012 Jul; 11():86. PubMed ID: 22762542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice.
    MacDonald ML; Singaraja RR; Bissada N; Ruddle P; Watts R; Karasinska JM; Gibson WT; Fievet C; Vance JE; Staels B; Hayden MR
    J Lipid Res; 2008 Jan; 49(1):217-29. PubMed ID: 17960025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Berberine up-regulates hepatic low-density lipoprotein receptor through Ras-independent but AMP-activated protein kinase-dependent Raf-1 activation.
    Li Z; Jiang JD; Kong WJ
    Biol Pharm Bull; 2014; 37(11):1766-75. PubMed ID: 25196457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.
    Kockx M; Glaros E; Leung B; Ng TW; Berbée JF; Deswaerte V; Nawara D; Quinn C; Rye KA; Jessup W; Rensen PC; Meikle PJ; Kritharides L
    Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1338-49. PubMed ID: 27150391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flaxseed reduces plasma cholesterol levels in hypercholesterolemic mouse models.
    Pellizzon MA; Billheimer JT; Bloedon LT; Szapary PO; Rader DJ
    J Am Coll Nutr; 2007 Feb; 26(1):66-75. PubMed ID: 17353585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of Transcription Factor CREBH Accelerates Diet-Induced Atherosclerosis in Ldlr-/- Mice.
    Park JG; Xu X; Cho S; Lee AH
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1772-81. PubMed ID: 27417587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice.
    Vida M; Gavito AL; Pavón FJ; Bautista D; Serrano A; Suarez J; Arrabal S; Decara J; Romero-Cuevas M; Rodríguez de Fonseca F; Baixeras E
    Dis Model Mech; 2015 Jul; 8(7):721-31. PubMed ID: 26035386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr
    Al-Sharea A; Murphy AJ; Huggins LA; Hu Y; Goldberg IJ; Nagareddy PR
    Atherosclerosis; 2018 Apr; 271():166-176. PubMed ID: 29518749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
    Wu Y; Xu MJ; Cao Z; Yang C; Wang J; Wang B; Liu J; Wang Y; Xian X; Zhang F; Liu G; Chen X
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zingiber officinale extract administration diminishes steroyl-CoA desaturase gene expression and activity in hyperlipidemic hamster liver by reducing the oxidative and endoplasmic reticulum stress.
    Carnuta MG; Deleanu M; Barbalata T; Toma L; Raileanu M; Sima AV; Stancu CS
    Phytomedicine; 2018 Sep; 48():62-69. PubMed ID: 30195881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.
    Srivastava RA; Jahagirdar R; Azhar S; Sharma S; Bisgaier CL
    Mol Cell Biochem; 2006 Apr; 285(1-2):35-50. PubMed ID: 16477380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.